Fampridine

Active substance
Fampridine
Domain
Neurological disorders
Reason of inclusion in Horizonscan Geneesmiddelen
Generic
Main indication
Multiple sclerosis

1. Product

Current proprietary name
Fampyra (Biogen)
Mechanism of action
Ion channel blocker
Budgetting framework
Extramural (GVS)

2. Registration

Registration route
Centralised (EMA)
Type of trajectory
Normal trajectory
Submission date
September 2019
Expected Registration
September 2020
Registration phase
Registration application pending
Additional comments
SPC Fampridine (Biogen) verloopt op 24 juli 2026.

3. Therapeutic value

Therapeutic value
Potential equal value
Duration of treatment
Not found

4. Expected patient volume per year

Patiëntvolume is niet van toepassing bij generieke geneesmiddelen of biosimilars.

5. Expected cost per patient per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

6. Potential total cost per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

There is currently nothing known about indication extensions.

9. Other information

There is currently no futher information available.